Yükleniyor... / Loading...
This study investigated disease-related biomarkers in patients with Duchenne muscular dystrophy (DMD). It enrolled genetically confirmed patients over 3 years old and above 15 kg, along with healthy individuals for comparison. It was conducted as a trial with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * FOR PATIENTS: * Diagnosis of DMD confirmed by genetic testing * Age over 3 years * Weight over 15 kg * Informed consent signed * FOR CONTROLS: * Age over 3 years * Male gender * Weight over 15 kg * Subjects with national health insurance coverage * Informed consent signed * Nonacute or chronic muscular, allergic, infectious, endocrine or inflammatory disorder in the 3 weeks preceding inclusion Exclusion Criteria: * FOR PATIENTS: * Concomitant chronic or acute muscular, endocrine, infectious, allergic or inflammatory disorder in the three weeks preceding the blood test * Intake of medicines other than angiotensin-converting enzyme inhibitors, beta blockers, dietary supplements, vitamins, alendronate and methylphenidate. Steroids (and medicines prescribed with them such as calcium supplements and proton pump inhibitors) will be discussed * Mental retardation or autism * Vaccination or treatment with immunoglobulins within the three months preceding inclusion * FOR CONTROLS: * Concomitant chronic or acute muscular, neurological (including mental retardation and autism), infectious or inflammatory disorder in the three weeks preceding the blood test * Vaccination or treatment with immunoglobulins within the three months preceding inclusion